Cancer Genetics (NASDAQ:CGIX) Stock Passes Below 50-Day Moving Average of $0.18

Shares of Cancer Genetics Inc (NASDAQ:CGIX) crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $0.18 and traded as low as $0.16. Cancer Genetics shares last traded at $0.17, with a volume of 2,383 shares trading hands.

The firm’s 50 day simple moving average is $0.18. The company has a current ratio of 0.36, a quick ratio of 0.36 and a debt-to-equity ratio of 0.24.

Cancer Genetics (NASDAQ:CGIX) last released its quarterly earnings results on Monday, May 20th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter. The business had revenue of $6.84 million for the quarter. Cancer Genetics had a negative net margin of 77.28% and a negative return on equity of 175.72%.

Hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new position in Cancer Genetics during the first quarter worth $48,000. Geode Capital Management LLC raised its stake in Cancer Genetics by 106.6% during the fourth quarter. Geode Capital Management LLC now owns 221,803 shares of the medical research company’s stock worth $53,000 after buying an additional 114,448 shares during the last quarter. Vanguard Group Inc. raised its stake in Cancer Genetics by 119.8% during the third quarter. Vanguard Group Inc. now owns 532,426 shares of the medical research company’s stock worth $554,000 after buying an additional 290,146 shares during the last quarter. Finally, Perkins Capital Management Inc. raised its stake in Cancer Genetics by 649.9% during the first quarter. Perkins Capital Management Inc. now owns 3,136,528 shares of the medical research company’s stock worth $753,000 after buying an additional 2,718,278 shares during the last quarter. 10.60% of the stock is owned by hedge funds and other institutional investors.

About Cancer Genetics (NASDAQ:CGIX)

Cancer Genetics, Inc develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology and immuno-oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.

Recommended Story: What is the Coverage Ratio?

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.